|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
No one seemed to notice, but IMUL got a nice $700K grant this week to help the company's research for its cocaine vaccine. This is IMUL's third major research program, after allergies (2 Phase III trials underway) and MS (1 Phase I trial to start shortly). Next up after cocaine will be vaccines for poison ivy.
The stock's starting to move up, but I doubt it will go very far until IMUL announces its new partner for its Allervax programs. Hopefully we'll hear more about this before year end.
|© 2021 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|